Oral sirolimus for prevention of recurrent infrainguinal arterial obstructions after surgical and endovascular revascularizations.
No data are currently available on the role of oral sirolimus in the prevention of recurrent stenosis in the periphery. We report the effects of oral sirolimus in the prevention of recurrent infrainguinal obstructions in patients with complex peripheral arterial disease. Three patients with ischemic rest pain of the lower limbs and repeated short-term need for surgical and/or endovascular revascularization: 9 times within 12 months, 7 times within 15 months, 11 times within 26 months, respectively. Oral sirolimus on a case by case basis, resulted in less frequent restenosis and longer intervention-free intervals: three re-interventions within 37 months in the first patient, one balloon angioplasty within 17 months in the second, and three re-interventions within 21 months in the third patient, respectively. Side effects, in particular dyspepsia and diarrhoea, were mild and tolerable. To our knowledge, this is the first report to show that oral sirolimus was successfully administered in patients with recurrent excessive neointimal proliferation after revascularization of peripheral arterial lesions lowering the necessity of re-intervention and hence prolonging intervention-free intervals.
Keo
H
H
Swiss Cardiovascular Center, Division of Angiology, Inselspital, University Hospital and University of Bern, Switzerland. keo.hakhong@insel.ch
Do
D
D
Husmann
M
M
Baumgartner
I
I
D000284:Administration, Oral; D000368:Aged; D000800:Angioplasty, Balloon; D002317:Cardiovascular Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003251:Constriction, Pathologic; D005260:Female; D006801:Humans; D007511:Ischemia / Q000150:complications / Q000188:drug therapy / Q000209:etiology / Q000601:surgery / Q000628:therapy*; D035002:Lower Extremity / Q000098:blood supply*; D008297:Male; D008875:Middle Aged; D016491:Peripheral Vascular Diseases / Q000150:complications / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D012086:Reoperation; D012501:Saphenous Vein / Q000637:transplantation; D055502:Secondary Prevention; D020123:Sirolimus / Q000008:administration & dosage* / Q000009:adverse effects; D017131:Thrombectomy; D017211:Treatment Failure; D014656:Vascular Surgical Procedures
D002317:Cardiovascular Agents; D020123:Sirolimus